TMO · NYSE · STOCK
Thermo Fisher Scientific (TMO) Stock Analysis
$690.12
52W $435.27 – $704.00
58/100
$257.53B
37.4
0.88
Is TMO Bullish or Bearish?
Bullish.
Innellis AI committee rates Thermo Fisher Scientific (TMO) Buy with a composite score of 58/100
, based on 5 analysts with 60% agreement.
Last updated October 16, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +16.92 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -3.08 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — 5 consecutive earnings beats -- consistent execution. Portfolio Manager remains cautious — sector concentration is already high (hhi 2739.42). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- News sentiment is positive (+0.33 across 70 articles, 14d) — News
Bear Case
- P/E of 36.5 is moderate-to-rich — Value
- Price-to-book of 4.1x prices in significant intangible value — Value
- RSI at 73 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 16, 2026
Overall Committee Score
58/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 42%
of 192 Healthcare peers
Value Analyst
bearish
35
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 36.5 is moderate-to-rich
Growth Analyst
bullish
68
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 73 is in overbought territory
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 70 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2739.42)
Investment Thesis Evolution
Committee score moved marginally from 58.3 to 58.1.
- Conviction changed from high to moderate.
- Committee agreement fell sharply from 80% to 60%.
- New bearish signals: 5 appeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- News Analyst: score 62->68 (+6); +1 bullish signal(s).
- Portfolio Manager: +1 bearish signal(s).
- Technical Analyst: stance bullish->neutral; score 61->54 (-8); +3 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-15 to 2026-10-16 (1 day apart).
Technical Analysis
RSI (14)
73.1
Overbought
MACD Histogram
-0.286
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
1.12
Above Upper Band
Price vs Moving Averages
EMA 9
$670.26
Above
EMA 21
$660.38
Above
EMA 50
$632.10
Above
EMA 200
$562.73
Above
Fundamental Analysis
Valuation
19
Growth
73
Profitability
63
Financial Health
74
Cash Flow
70
Valuation
P/E Ratio
37.4×
P/B Ratio
4.91×
PEG Ratio
5.03
Dividend Yield
0.26%
52W High
$704.00
52W Low
$435.27
Quality & Growth
ROE
1261.5%
ROA
610.6%
Gross Margin
4103.3%
Operating Margin
1797.1%
Revenue Growth YoY
—
Debt / Equity
0.81
AI Fundamental Assessment
P/E ratio of 37.4 (rich relative to a 15-40x range); Price-to-book of 4.9x; PEG ratio of 5.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 12.6%; Return on assets of 6.1%; Net margin of 15.1%; Gross margin of 41.0%; Current ratio of 1.55 (healthy short-term liquidity); Debt-to-equity of 0.81; Free cash flow per share is positive (19.73); Most recent quarter beat estimates by 4.5%; 5 consecutive earnings beats; EPS growth accelerating (-17.2% -> +10.8% QoQ); Average YoY EPS growth of 12.5%; Analyst estimates falling over recent quarters
Get the Full TMO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →